The emerging role of co-stimulatory molecules and their agonistic mAb-based combination therapies in melanoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): He S;He S; Xu J; Xu J; Wu J; Wu J
  • Source:
    International immunopharmacology [Int Immunopharmacol] 2020 Dec; Vol. 89 (Pt B), pp. 107097. Date of Electronic Publication: 2020 Oct 19.
  • Publication Type:
    Journal Article; Review
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Amsterdam ; New York : Elsevier Science, c2001-
    • Subject Terms:
      Antibodies, Monoclonal/*therapeutic use ; Costimulatory and Inhibitory T-Cell Receptors/*immunology ; Melanoma/*therapy ; Receptors, Antigen, T-Cell/*immunology; Animals ; Combined Modality Therapy/methods ; Costimulatory and Inhibitory T-Cell Receptors/metabolism ; Humans ; Receptors, Antigen, T-Cell/metabolism
    • Abstract:
      Although anti-PD-1/L1 and anti-CTLA-4 antibodies, the validated immune checkpoint blockades, can elicit durable long-lasting antitumor immunity and improve the clinical outcomes of melanoma treatment, there are still a fraction of patients who did not receive therapeutic benefits as expected. In addition to findings of blocking the co-inhibitory pathways, the preclinical and clinical evidence suggests that triggering the co-stimulatory pathways through agonists such as CD137, OX40, CD40, GITR and CD27 may be a rational next step for melanoma therapy. In this review, we discuss the progress of studies on these co-stimulatory molecules in terms of their promising therapeutic effects and underlying antitumor mechanisms, and provide a review of the possible combinations that orchestrate the interplay of co-stimulatory agonistic mAbs and other therapies for treating melanoma, including inhibitory immune checkpoint mAbs, adoptive T cell therapy, chemotherapy and radiotherapy. We also briefly present the limitations and challenges involved in these co-stimulatory agonistic mAb-based combination strategies for melanoma patients.
      (Copyright © 2020 Elsevier B.V. All rights reserved.)
    • Contributed Indexing:
      Keywords: Co-stimulatory molecules; Combination; Immunotherapy; Melanoma; Monoclonal antibody
    • Accession Number:
      0 (Antibodies, Monoclonal)
      0 (Costimulatory and Inhibitory T-Cell Receptors)
      0 (Receptors, Antigen, T-Cell)
    • Publication Date:
      Date Created: 20201022 Date Completed: 20210420 Latest Revision: 20210420
    • Publication Date:
      20240105
    • Accession Number:
      10.1016/j.intimp.2020.107097
    • Accession Number:
      33091814